Prostate cancer is the most common cancer in men and is second most common cause of cancer deaths. Importantly, the annual rates of prostate cancer incidence continue to rise. 

This session will delve into how pathology, genomics and biomarkers guide the management and treatment of prostate cancer and equip you with a comprehensive understanding of this cancer.

Learning Objectives

At the end of this presentation, the participants will be able to:

• Distinguish between normal prostate tissue and various histological subtypes of prostate cancer.
• Grasp the significance of Gleason grading and Gleason Grade Groups and other prognostic factors in prostate cancer.
• Demonstrate role of immunohistochemistry and other advanced diagnostic techniques.
• Review the timing and role of molecular testing
• Discuss the role of biomarkers in guiding immunotherapy (IO), antibody-conjugated drugs (ADC) and radio-ligand therapies (RLT)
• Identify how pathological assessment drives clinical decision-making
• Define how biomarkers guide treatment